The presentation of long-term data from a clinical study can significantly impact a biotech company's stock price. Positive results could lead to increased investor confidence and a potential stock price increase, while negative results could have the opposite effect. The announcement of the presentation itself suggests that BridgeBio Pharma is confident in the data, which may lead to a positive short-term impact on the stock price.